These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21406339)

  • 1. Metal ions, Alzheimer's disease and chelation therapy.
    Budimir A
    Acta Pharm; 2011 Mar; 61(1):1-14. PubMed ID: 21406339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics.
    Duce JA; Bush AI
    Prog Neurobiol; 2010 Sep; 92(1):1-18. PubMed ID: 20444428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease, metal ions and metal homeostatic therapy.
    Zatta P; Drago D; Bolognin S; Sensi SL
    Trends Pharmacol Sci; 2009 Jul; 30(7):346-55. PubMed ID: 19540003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations.
    Jellinger KA
    Int Rev Neurobiol; 2013; 110():1-47. PubMed ID: 24209432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metals ions and neurodegeneration.
    Molina-Holgado F; Hider RC; Gaeta A; Williams R; Francis P
    Biometals; 2007 Jun; 20(3-4):639-54. PubMed ID: 17294125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
    Mancino AM; Hindo SS; Kochi A; Lim MH
    Inorg Chem; 2009 Oct; 48(20):9596-8. PubMed ID: 19817493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.
    Gaeta A; Hider RC
    Br J Pharmacol; 2005 Dec; 146(8):1041-59. PubMed ID: 16205720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-β aggregation.
    Choi JS; Braymer JJ; Park SK; Mustafa S; Chae J; Lim MH
    Metallomics; 2011 Mar; 3(3):284-91. PubMed ID: 21210061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy.
    Zheng H; Youdim MB; Fridkin M
    J Med Chem; 2009 Jul; 52(14):4095-8. PubMed ID: 19485411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
    Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
    J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of cyclo-phen-type ligands: chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases.
    Boldron C; Van der Auwera I; Deraeve C; Gornitzka H; Wera S; Pitié M; Van Leuven F; Meunier B
    Chembiochem; 2005 Nov; 6(11):1976-80. PubMed ID: 16208731
    [No Abstract]   [Full Text] [Related]  

  • 12. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
    Liu G; Men P; Harris PL; Rolston RK; Perry G; Smith MA
    Neurosci Lett; 2006 Oct; 406(3):189-93. PubMed ID: 16919875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
    Cui Z; Lockman PR; Atwood CS; Hsu CH; Gupte A; Allen DD; Mumper RJ
    Eur J Pharm Biopharm; 2005 Feb; 59(2):263-72. PubMed ID: 15661498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.
    Zheng H; Youdim MB; Fridkin M
    ACS Chem Biol; 2010 Jun; 5(6):603-10. PubMed ID: 20455574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
    Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metal attenuating therapies in neurodegenerative disease.
    Mot AI; Wedd AG; Sinclair L; Brown DR; Collins SJ; Brazier MW
    Expert Rev Neurother; 2011 Dec; 11(12):1717-45. PubMed ID: 22091597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyquinoline based binders: promising ligands for chelatotherapy?
    Budimir A; Humbert N; Elhabiri M; Osinska I; Biruš M; Albrecht-Gary AM
    J Inorg Biochem; 2011 Mar; 105(3):490-6. PubMed ID: 20926137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease.
    Robert A; Liu Y; Nguyen M; Meunier B
    Acc Chem Res; 2015 May; 48(5):1332-9. PubMed ID: 25946460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unusual Cyclodextrin Derivatives as a New Avenue to Modulate Self- and Metal-Induced Aβ Aggregation.
    Oliveri V; Bellia F; Pietropaolo A; Vecchio G
    Chemistry; 2015 Sep; 21(40):14047-59. PubMed ID: 26298549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chelating agents for neurodegenerative diseases.
    Ward RJ; Dexter DT; Crichton RR
    Curr Med Chem; 2012; 19(17):2760-72. PubMed ID: 22489724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.